Johnson & Johnson Faces Legal and Growth Challenges Amid Market Lag
Johnson & Johnson (JNJ 1.53%), a healthcare giant by market cap, has underperformed the market in recent years. Persistent legal battles over talc-based products and looming patent expirations threaten its revenue stability. The company's attempt to settle lawsuits via bankruptcy maneuvers has faced judicial rejection, prolonging brand damage.
Key growth inhibitors include the loss of U.S. patent exclusivity for Stelara, a blockbuster immunosuppressant, and new Medicare pricing policies. These factors compound investor skepticism about J&J's long-term prospects in an increasingly competitive pharmaceutical landscape.